Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-12

  Comin Anduix, Begoña ^a,b   Sazegar, Hooman ^a   Chodon, Thinle ^a   Matsunaga, Douglas ^a   Jalil, Jason ^a   von Euw, Erika ^a   Escuin Ordinas, Helena ^a   Balderas, Robert ^c   Chmielowski, Bartosz ^a   Gomez Navarro, Jesus ^d,e   Koya, Richard C ^a   Ribas, Antoni ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BD BIOSCIENCES   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; LAT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN KINASE LCK; PROTEIN KINASE ZAP 70; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; SYNAPTOPHYSIN; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; BLOCKING ANTIBODY; CTLA4 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOPHYSITIS; IN VITRO STUDY; MALE; MELANOMA; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN PHOSPHORYLATION; PRURITUS; SIGNAL TRANSDUCTION; DRUG EFFECT; IMMUNOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CTLA-4 ANTIGEN; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION;

EID: 77958553315     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012711     Document Type: Article

References (46)

1. Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19: 565-594.
2. Teft WA, Kirchhof MG, Madrenas J (2006) A Molecular Perspective Of Ctla-4 Function. Annu Rev Immunol 24: 65-97.
3. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, et al. (1998) Molecular basis of T cell inactivation by CTLA-4. Science 282: 2263-2266.
4. Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183: 2533-2540.
5. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH (2001) CTLA-4 regulates induction of anergy in vivo. Immunity 14: 145-155.
6. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, et al. (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.
7. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, et al. (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
8. Wang XB, Giscombe R, Yan Z, Heiden T, Xu D, et al. (2002) Expression of CTLA-4 by human monocytes. Scand J Immunol 55: 53-60.
9. Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, et al. (2007) Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12: 873-883.
10. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, et al. (2005) Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23: 8968-8977.
11. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, et al. (2009) Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27: 1075-1081.
12. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, et al. (2009) Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3- Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade. Clin Cancer Res 15: 390-399.
13. Ribas A, Hauschild A, Kefford R, Punt CA, Haanen JB, et al. (2008) Phase III, Open-Label, Randomized, Comparative Study of Tremelimumab (CP-675,206) and Chemotherapy (Temozolomide or Dacarbazine) in Patients with Advanced Melanoma. Journal of Clinical Oncology 26: abstr LBA9011.
14. Marengere LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS, et al. (1996) Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 272: 1170-1173.
15. Srahna M, Van Grunsven LA, Remacle JE, Vandenberghe P (2006) CTLA-4 interacts with STAT5 and inhibits STAT5-mediated transcription. Immunology 117: 396-401.
16. Ueda H, Howson JM, Esposito L, Heward J, Snook H, et al. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511.
17. Maier LM, Anderson DE, De Jager PL, Wicker LS, Hafler DA (2007) Allelic variant in CTLA4 alters T cell phosphorylation patterns. Proc Natl Acad Sci U S A 104: 18607-18612.
18. Alegre ML, Frauwirth KA, Thompson CB (2001) T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1: 220-228.
19. Shrikant P, Khoruts A, Mescher MF (1999) CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11: 483-493.
20. Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI (1999) In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A 96: 11476-11481.
21. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
22. Parry RV, Reif K, Smith G, Sansom DM, Hemmings BA, et al. (1997) Ligation of the T cell co-stimulatory receptor CD28 activates the serine-threonine protein kinase protein kinase B. Eur J Immunol 27: 2495-2501.
23. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, et al. (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25: 9543-9553.
24. Chuang E, Fisher TS, Morgan RW, Robbins MD, Duerr JM, et al. (2000) The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity 13: 313-322.
25. Schneider H, Valk E, Leung R, Rudd CE (2008) CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death. PLoS ONE 3: e3842.
26. Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB (1998) Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc Natl Acad Sci U S A 95: 11107-11112.
27. Wang YZ, Wharton W, Garcia R, Kraker A, Jove R, et al. (2000) Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene 19: 2075-2085.
28. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, et al. (2004) Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118: 217-228.
29. Krutzik PO, Irish JM, Nolan GP, Perez OD (2004) Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 110: 206-221.
30. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, et al. (2004) Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27: 354-367.
31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors [see comments]. J Natl Cancer Inst 92: 205-216.
32. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, et al. (2008) Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 6: 22.
33. Perfetto SP, Chattopadhyay PK, Roederer M (2004) Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 4: 648-655.
34. Krutzik PO, Nolan GP (2006) Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 3: 361-368.
35. Perez OD, Krutzik PO, Nolan GP (2004) Flow cytometric analysis of kinase signaling cascades. Methods Mol Biol 263: 67-94.
36. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100: 8372-8377.
37. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, et al. (2005) Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23: 741-750.
38. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, et al. (2008) CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105: 14987-14992.
39. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, et al. (2009) Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106: 2729-2734.
40. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, et al. (2003) Determinant Spreading Associated with Clinical Response in Dendritic Cellbased Immunotherapy for Malignant Melanoma. Clin Cancer Res 9: 998-1008.
41. Carey GB, Semenova E, Qi X, Keegan AD (2007) IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway. Cell Res 17: 942-955.
42. So EY, Oh J, Jang JY, Kim JH, Lee CE (2007) Ras/Erk pathway positively regulates Jak1/STAT6 activity and IL-4 gene expression in Jurkat T cells. Mol Immunol 44: 3416-3426.
43. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, et al. (2009) CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 7: 35.
44. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, et al. (2007) Downregulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4: e176.
45. Weber J (2009) Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58: 823-830.
46. Di Giacomo AM, Danielli R, Guidoboni M, Calabro L, Carlucci D, et al. (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58: 1297-1306.